What drove the significant increase in Amgen's revenue and net income?

The substantial growth in revenue was primarily driven by strong performance across key products, including Enbrel, Neulasta, Xgeva, Sensipar/Mimpara, and Prolia, which saw increased demand and higher net selling prices. This revenue growth, coupled with improved operating efficiencies and lower restructuring charges compared to the prior year, led to a significant increase in operating income and, consequently, net income and EPS.

How is Amgen managing the threat of biosimilar competition?

Amgen is actively defending its market position against biosimilar competitors by engaging in patent litigation and pursuing regulatory strategies. The company highlights ongoing lawsuits against manufacturers of biosimilar versions of its key products like NEUPOGEN® and Neulasta®, and it is closely monitoring regulatory developments and patent expirations that could enable biosimilar entry.

What is the company's strategy for returning capital to shareholders?

Amgen is committed to returning capital to shareholders through a combination of cash dividends and share repurchases. For the nine months ended September 30, 2015, the company paid dividends totaling $2.37 per share and repurchased approximately $1.7 billion of its common stock. The company also authorized an increase in its stock repurchase program, indicating continued confidence in its ability to generate cash flow.

Are there any significant new product developments or approvals?

Yes, a notable development was the FDA approval of Repatha™ in August 2015, an innovative treatment for certain cardiovascular conditions. Additionally, the company has advanced the regulatory submissions for other pipeline candidates, such as etelcalcetide for secondary hyperparathyroidism and BLINCYTO® and IMLYGIC™ for oncology indications, demonstrating continued progress in its drug development pipeline.

AMGN 10-Q Quarterly Report Q3 FY2015 — Revenue, Net Income, EPS

Summary

Amgen Inc. (AMGN) reported strong financial performance for the nine months ended September 30, 2015, demonstrating significant growth in revenues and net income compared to the prior year. Total revenues increased by 9% to $16.1 billion, primarily driven by a 10% rise in product sales to $14.2 billion. This growth was fueled by key products such as Enbrel, Neulasta, Xgeva, and Sensipar/Mimpara, which showed robust sales increases across various regions, particularly in the U.S. Profitability also saw substantial improvement, with net income rising by 33% to $5.1 billion and diluted Earnings Per Share (EPS) increasing by 33% to $6.70. This enhanced profitability is attributed to higher revenues, improved operating income, and a reduction in operating expenses, partly due to cost-saving restructuring efforts initiated in the prior year. The company also actively returned capital to shareholders through dividends and a significant stock repurchase program, signaling confidence in its financial health and future prospects.

Financial Highlights

55 data points

Beta

Revenue

$5.72B

0.8% Gross Margin

Net Income

$1.86B

0.3% Net Margin

EPS (Diluted)

$2.44

Total Assets

$71.87B

Cash & Equivalents

$3.23B

Free Cash Flow

$2.75B

Financial Statements

Beta

Revenue	$5.72B
Cost of Revenue	$1.03B
Gross Profit	$4.48B
SG&A Expenses	$1.24B
Operating Expenses	$3.38B
Operating Income	$2.34B
Interest Expense	$282.00M
Net Income	$1.86B
EPS (Basic)	$2.46
EPS (Diluted)	$2.44
Shares Outstanding (Basic)	757.00M
Shares Outstanding (Diluted)	764.00M

Key Highlights

1Total revenues increased by 9% to $16.1 billion for the nine months ended September 30, 2015, up from $14.7 billion in the prior year.
2Product sales grew by 10% to $14.2 billion, driven by strong performance in key products like Enbrel, Neulasta, Xgeva, Sensipar/Mimpara, and Prolia.
3Net income rose significantly by 33% to $5.1 billion, and diluted EPS increased by 33% to $6.70, reflecting improved profitability.
4Operating expenses decreased by 3% due to lower restructuring charges compared to the prior year and ongoing cost-saving initiatives.
5The company paid $2.37 per share in dividends year-to-date and repurchased $1.7 billion of its common stock during the first nine months of 2015.
6Amgen received FDA approval for Repatha™ for certain cardiovascular conditions in August 2015, expanding its product portfolio.
7The company is actively managing potential competition from biosimilars through patent litigations and market strategies.

AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2015

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions